Expanding the differential for diarrhea beyond Clostridium difficile.
A research team from the Netherlands turns to deep sequencing technology to detect hepatitis C virus resistant variants.
A quick debrief of the week’s top FDA approvals, FDA authorizations, or other infectious disease pipeline developments from the past week.
Biofilms are an emerging clinical problem despite the fact that most clinicians don’t even think of biofilms when managing infections.
Men who have sex with men who seek out sexual partners online are more likely to report sexually transmitted infections, including syphilis, gonorrhea, and chlamydia.
Debra Goff, PharmD, discusses her advocacy around this topic and bringing the stewardship message to dentists about how antibiotic prescribing practices have changed and getting them to recalibrate their thinking and actions in their field.
With IV drug use accounting for 60% of new infections, treatment for individuals in this population is necessary to stave off new infections.
This In the Literature piece explores if we can mitigate some of the adverse reactions that are being seen in obese patients who receive vancomycin through AUC-dosing.
Infections transmitted by these bloodsucking species are on the rise worldwide.
Amesh A. Adalja, MD, FIDSA argues that a bill being considered in the Pennsylvania state legislature will ultimately result in increased antibiotic resistance and will set back the clock for finding appropriate treatments for Lyme disease.
Many health care facilities are looking to expand the use of broad-spectrum sporicidal disinfectants beyond patient isolation rooms to better address the role of the environment in pathogen transmission and acquisition.
This week, the FDA approved two new drugs, gepotidacin for treating uUTIs in females aged 12 and older, and Tesamorelin F8 for managing excess abdominal fat in adults with HIV-associated lipodystrophy.
This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.
Contagion® Editorial Advisory Board member, Khalid Eljaaly, PharmD, BCPS, CAPP, discusses key updates in the Infectious Diseases Society of America and the American Thoracic Society recommendations.
The National Institutes of Health has awarded a 4-year, $4.8 million grant to the University of Arizona to speed up the development of delta-CPS1, a vaccine candidate to fight valley fever.
This time of year means new trainees will begin their careers and are excited to take on research projects. However, they may have limited to no experience in this area. Here is an opportunity to give them structure and guidance when committing to longitudinal trainee research.
Health officials in China have confirmed a case of bubonic plague in a herdsman from the Inner Mongolia district, triggering increased prevention measures throughout the region.
This is the second in a series looking at the intersection of government and public health. In this segment, Contagion Editor-in-Chief Jason Gallagher, FCCP, FIDP, FIDSA, BCPS, discusses the WHO pullout, and the pauses on federal communication and research grants.
In 2017, lower respiratory tract infections linked with influenza were responsible for an estimated 145,000 deaths worldwide.
We review current and emerging treatment options for infections caused by the difficult-to-treat, intrinsically multidrug-resistant organism Stenotrophomonas maltophilia.
This virus has multiple facets and highlights a need for real-time learning.
“A bite bug in the belly.”
Despite having emerged as either the third or fourth leading cause of blood stream infections in the United States, the threat of multi-drug resistant Candida species remains an underappreciated concern.
Parallels between the recent Zika epidemic in Brazil and the HIV pandemic in the 1980s, stress the importance of improving responses to public health crises.
Exploring the challenges and strategies for combating MDR Pseudomonas aeruginosa infections, as discussed with Jason Pogue, PharmD, BCPS, BCIDP